Go Pro
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel
NASDAQ:TCRX

TScan Therapeutics Q4 2024 Earnings Report

TScan Therapeutics logo
$1.26 +0.19 (+17.76%)
Closing price 04:00 PM Eastern
Extended Trading
$1.25 -0.01 (-0.87%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

TScan Therapeutics EPS Results

Actual EPS
-$0.29
Consensus EPS
-$0.27
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A

TScan Therapeutics Revenue Results

Actual Revenue
$0.67 million
Expected Revenue
$1.43 million
Beat/Miss
Missed by -$760.00 thousand
YoY Revenue Growth
N/A

TScan Therapeutics Announcement Details

Quarter
Q4 2024
Date
3/5/2025
Time
Before Market Opens
Conference Call Date
Wednesday, March 5, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

TScan Therapeutics' Q2 2026 earnings is estimated for Tuesday, August 11, 2026, based on past reporting schedules, with a conference call scheduled at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

TScan Therapeutics' Q4 2024 Press ReleasePress Release
(8-K)
TScan Therapeutics' Q4 2024 Annual reportAnnual report
(10-K)

TScan Therapeutics Earnings Headlines

TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
June 24, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/24/3316713/0/en/tscan-therapeutics-to-participate-in-the-h-c-wainwright-4th-annual-cell-therapy-virtual-conference.html
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic ...
June 23, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/tscan-therapeutics-announces-positive-initial-data-from-cohort-c-of-ongoing-alloha-phase-1-study-evaluating-tsc-101-in-patients-with-heme-malignancies-undergoing-allogeneic-hematopoietic-cell-1036264745
Sell Tesla, Buy the New King of FSD Cars
In 2023, Marc Chaikin's system flagged an automotive stock as bearish - and it fell 35% shortly after. Today, that same stock has earned a 'Very Bullish' rating after forming a major partnership with Nvidia to power AI-driven autonomous vehicles. This barely-known company was selected to handle the complex job of getting Nvidia's self-driving AI safely inside vehicles - positioning it at the center of a massive trend most investors are still missing through Tesla.tc pixel
July 8 at 1:00 AM  |  Chaikin Analytics (Ad)
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation
June 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/22/3315162/0/en/tscan-therapeutics-announces-positive-initial-data-from-cohort-c-of-ongoing-alloha-phase-1-study-evaluating-tsc-101-in-patients-with-heme-malignancies-undergoing-allogeneic-hematop.html
Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies
June 3, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260603703141/en/cellares-and-tscan-therapeutics-announce-agreement-to-evaluate-automated-manufacturing-of-tsc-101-for-patients-with-hematologic-malignancies/
TScan Therapeutics, Inc. (TCRX) Reports Q1 2026 Results With Improved Net Loss
June 2, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/tscan-therapeutics-inc-tcrx-reports-q1-2026-results-with-improved-net-loss-1773515/
See More TScan Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like TScan Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TScan Therapeutics and other key companies, straight to your email.

About TScan Therapeutics

TScan Therapeutics (NASDAQ:TCRX) is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors. TScan has established strategic collaborations with major pharmaceutical partners to advance its lead candidates through clinical development. These partnerships enable the company to combine its TCR discovery capabilities with the resources and expertise of established drug developers, while retaining the ability to progress additional assets independently.

Founded in 2018 and headquartered in Cambridge, Massachusetts, TScan Therapeutics went public in late 2021. Under the leadership of Chief Executive Officer Kenneth Song, the company employs a multidisciplinary team of immunologists, molecular biologists and data scientists. While its core operations are based in the United States, TScan’s research partnerships and clinical trial activities extend globally, reflecting its ambition to deliver novel T-cell therapies to patients around the world.

View TScan Therapeutics Profile
Earnings Tools